SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-003373
Filing Date
2024-01-05
Accepted
2024-01-05 16:11:55
Documents
19
Period of Report
2024-01-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d103567d8k.htm   iXBRL 8-K 42411
2 EX-1.1 d103567dex11.htm EX-1.1 206904
3 EX-4.1 d103567dex41.htm EX-4.1 79053
4 EX-5.1 d103567dex51.htm EX-5.1 11048
5 EX-99.1 d103567dex991.htm EX-99.1 11143
6 EX-99.2 d103567dex992.htm EX-99.2 12159
10 GRAPHIC g103567g0105020735663.jpg GRAPHIC 2744
11 GRAPHIC g103567g0105022042179.jpg GRAPHIC 3135
  Complete submission text file 0001193125-24-003373.txt   586434

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA kymr-20240104.xsd EX-101.SCH 2852
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20240104_lab.xml EX-101.LAB 17993
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20240104_pre.xml EX-101.PRE 11262
13 EXTRACTED XBRL INSTANCE DOCUMENT d103567d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 24516346
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)